+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of NNC0497-0040 in healthy adults with normal weight or overweight, adults with overweight or obesity, and adults with type 1 diabetes who also have overweight or obesity. This phase 1 clinical trial aims to understand how this new treatment compares to a placebo in these different groups. The sponsor of the study is Novo Nordisk AS. Participants will receive weekly subcutaneous injections of either NNC0497-0040 or a matching placebo. The study includes multiple groups single ascending dose SAD and multiple ascending dose MAD cohorts. Each participant will receive either the investigational drug or placebo for up to 29 weeks, depending on their assigned group. During the trial, participants will have regular assessments including medical exams, vital signs, electrocardiograms, and laboratory tests to monitor safety and drug effects. Researchers will track the number of adverse events from the start of treatment through various weeks depending on the cohort, along with measuring drug levels in the blood. Participants glucose control and hypoglycemic episodes will also be monitored, especially for those with type 1 diabetes. The total participation time may last up to 29 weeks.

Age: 18Years - 55YearsAll GendersPhase 1
1 location
I

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new medicine called NNC9733-0001 for its potential to help people with type 2 diabetes manage high blood sugar levels. The study also includes healthy participants to compare safety and tolerance. This Phase 1 trial aims to assess how safe and tolerable the medicine is when given as a single dose. Participants will be randomly assigned to receive either the study medicine or a placebo, which contains no active medicine. The dose strength is determined by when the participant enters the study, and the medicine is given as one or up to four injections around the abdomen by medical staff. The total study duration is about 40 weeks 10 months. During the study, participants will be monitored for side effects and any low blood sugar events from dosing until the end of the study at week 36. Blood samples will be collected to measure how the medicine behaves in the body over 48 hours after dosing. Participants will have regular assessments including physical exams, vital signs, ECGs, and laboratory tests to track safety and how the medicine is processed. The study includes healthy volunteers and people with type 2 diabetes aged 18 to 64 years.

Age: 18Years - 64YearsAll GendersPhase 1
1 location
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of the drug ZP6590 in healthy adult men with normal weight, overweight, or obesity. The study also aims to understand how the body absorbs, distributes, and eliminates ZP6590. This early-phase, randomized, double-blind, placebo-controlled trial focuses on single ascending doses and multiple ascending doses of the drug. The trial has two parts. In the first part, participants receive a single subcutaneous dose of ZP6590 or placebo, followed by a four-week observation period. In the second part, participants receive multiple subcutaneous doses of ZP6590 or placebo over six or twelve weeks, with a six-week observation period after the last dose. Dose escalation decisions are based on safety and exposure assessments. Participants will be screened for eligibility and admitted to the study site before dosing. They may have ambulatory or in-house visits during dosing and follow-up. The study will monitor safety and tolerability throughout, with pharmacokinetic measurements taken after dosing to assess how the drug moves through the body. Total participation may last up to about 18 weeks depending on the treatment cohort.

Age: 18Years - 60YearsMALEEarly Phase 1
1 location
O

Actively Recruiting

Researchers are studying the clinical and health outcomes of amivantamab-containing treatments for people with common EGFR-mutated advanced non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can spread to other parts of the body. This observational study looks at how these treatments work in real-world clinical settings for patients with specific EGFR mutations. Participants include those with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations. Two groups are observed one receiving amivantamab combined with carboplatin and pemetrexed after previous therapy failure, and another receiving amivantamab with lazertinib as first-line treatment. No study drugs are provided data is collected from routine medical care. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, and medication use for up to about 60 months. Quality of life is assessed using the SKINDEX and EORTC QLQ-C30 questionnaires. The study tracks how patients respond to treatment and monitors safety outcomes, with participation lasting several years.

Age: 18Years +All Genders
90 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of eloralintide compared to a placebo on insulin sensitivity, metabolic health, and body weight in adults who are overweight or have obesity. This phase 1 study focuses on understanding how these treatments influence how the body responds to insulin and other metabolic factors. Participants in this study are adults aged 18 to 70 years with a body mass index between 25 and 45 kgm, and without diabetes. Participants will be randomly assigned to receive either eloralintide or a placebo, both administered by subcutaneous injection. The study lasts about 35 weeks and includes 3 inpatient visits totaling 7 days. The design is double-blind, so neither the participants nor the researchers know who receives the active drug or placebo during the trial. During the study, participants will undergo assessments to measure changes in insulin sensitivity using a hyperinsulinemic euglycemic clamp test at baseline and week 24. Body weight changes will also be tracked over the same period. Participants must maintain lifestyle and dietary guidelines throughout the study. The research team will monitor safety and overall health during the visits and follow the participants until study completion around 2027.

Age: 18Years - 70YearsAll GendersPhase 1
2 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY4057996 in healthy individuals and people with Type 1 or Type 2 Diabetes. This Phase 1 study aims to understand how well the drug is tolerated and what side effects may occur when administered through different methods. It includes both healthy participants and those with diabetes under various treatment conditions. Participants will receive LY4057996 either under the skin subcutaneously or into a vein in the arm intravenously. Some groups may receive placebo or other diabetes medications such as Degludec, Lispro, or basal insulin alongside LY4057996. The study is divided into parts lasting different durations Parts A1-A2 last about 11 weeks, A3-A5 about 4 weeks, Part B about 6 weeks, and Part C about 7 weeks, excluding screening. During the study, participants will undergo blood tests to measure how LY4057996 moves through and is eliminated by the body. Researchers will monitor for any serious or related side effects and track changes in fasting glucose and glucose infusion rates. The total study duration can be up to 47 weeks, including safety follow-up. Participants will have regular visits for assessments and monitoring throughout their assigned study part.

Age: 18Years +All GendersPhase 1
1 location
N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating GUB-UCN2, a new drug administered by injection, in healthy lean people, individuals with obesity, and those living with Type 2 Diabetes. This study involves a treatment period of up to 16 weeks in selected groups and compares GUB-UCN2 given alone or alongside standard obesity treatments to a placebo. The trial is designed to assess how safe and tolerable the drug is, as well as how it behaves in the body. Participants will be randomly assigned to receive either the investigational drug GUB-UCN2 or a placebo. The study includes three parts Part 1 involves healthy lean participants, Part 2 includes obese male participants, and Part 3 involves participants with obesity or Type 2 Diabetes with varying body mass index ranges. All doses are given subcutaneously. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will undergo medical history reviews, safety assessments, and laboratory tests. Researchers will monitor treatment-emergent adverse events for up to 22 weeks and measure pharmacokinetics such as drug concentration over time. Participants will be followed through screening, treatment, and observation periods to evaluate safety and how the drug is processed in the body. The entire trial runs until December 2028.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
1 location

1-10 of 30

1